Sarepta Therapeutics (SRPT) Consolidated Net Income (2010 - 2026)

Sarepta Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 173.96% year-over-year to $331.0 million; the TTM figure through Mar 2026 stood at $64.7 million (up 118.99% YoY), while the FY2025 annual figure was -$713.8 million, down 599.55% from the prior year.
• Consolidated Net Income was $331.0 million for Q1 2026 at Sarepta Therapeutics, up from -$283.2 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $331.0 million in Q1 2026 to a low of -$516.8 million in Q1 2023.
• Historically, Consolidated Net Income has averaged -$46.5 million across 5 years, with a median of -$23.9 million in 2023.
• Biggest YoY gain for Consolidated Net Income was 2939.86% in 2025; the steepest drop was 1337.99% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at $329.3 million in 2022, then decreased by 10.11% to $296.1 million in 2023, then plunged by 77.47% to $66.7 million in 2024, then slumped by 524.65% to -$283.2 million in 2025, then jumped by 216.86% to $331.0 million in 2026.
• The last three Consolidated Net Income figures came in at $331.0 million (Q1 2026), -$283.2 million (Q4 2025), and -$179.9 million (Q3 2025), per Business Quant data.